Efficacy and Safety of Dupilumab in Clinical Practice: One Year of Experience on 165 Adult Patients from a Tertiary Referral Centre

We have read with great interest the article by Kreeshan et al., which reported data on effectiveness and laboratory safety of dupilumab. We performed a retrospective study including 165 adult patients affected by moderate-to-severe atopic dermatitis (AD) and treated with dupilumab for at least 52 w...

Full description

Saved in:
Bibliographic Details
Published in:Dermatology and therapy 2021-04, Vol.11 (2), p.355-361
Main Authors: Napolitano, Maddalena, Ferrillo, Maria, Patruno, Cataldo, Scalvenzi, Massimiliano, D’Andrea, Mirella, Fabbrocini, Gabriella
Format: Article
Language:English
Subjects:
Atopic dermatitis
Commentary
Dermatology
Drug therapy
Internal Medicine
Medicine
Medicine & Public Health
Oral and Maxillofacial Surgery
Patient outcomes
Plastic Surgery
Quality of Life Research
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We have read with great interest the article by Kreeshan et al., which reported data on effectiveness and laboratory safety of dupilumab. We performed a retrospective study including 165 adult patients affected by moderate-to-severe atopic dermatitis (AD) and treated with dupilumab for at least 52 weeks. A significant improvement in eczema area severity index (EASI) score after 16 and 52 weeks of treatment with dupilumab was observed. The mean EASI score at baseline was 28.84 ± 6.4 and significantly reduced to 10.05 ± 8.00 at 16 weeks ( p  
ISSN:2193-8210
2190-9172
DOI:10.1007/s13555-021-00505-z